Core Clinical Research, located in downtown Everett is a local, independently owned, clinical research center specializing in conditions pertaining to the central nervous system. They’re currently seeking participants for a study of migraines on adolescents. Here’s more.
Core Clinical is located in downtown Everett. Click to visit their website.
— Core Clinical Research is actively recruiting migraine patients ages 12-17 for a new clinical research study evaluating the safety and effectiveness of an investigational migraine treatment in adolescents.
The World Health Organization classifies migraine as one of the 10 most disabling medical illnesses and occurs in approximately four to 11 percent of elementary school-aged children and eight to 15 percent of high school-aged adolescents.
This multicenter, placebo controlled, Phase 3 clinical trial is studying rimegepant as an investigational acute treatment. Rimegepant is approved by the U.S. Food and Drug Administration (FDA) to treat and prevent episodic migraine in adults and marketed as NURTEC® ODT.
“Migraine can be debilitating in adolescents, but often goes undiagnosed because they have a more difficult time understanding and expressing their pain,” said Primary Investigator James A. Knutson, MD at Core Clinical Research. “Limited treatment options for migraine are available for adolescents today. Rimegepant has shown effectiveness as an acute treatment in adults with migraine, and we are hopeful it will also help adolescents get relief and return more quickly to their daily life.”
Clinicians at Core Clinical Research are now seeking eligible participants for the study. To enroll, participants must be between age 12 and 17, have at least one migraine per month, and have at least a six-month history of migraine. For more information about participating in the study at Core Clinical Research call 425-443-9551 or visit www.pediatricmigrainestudy.com. You can also find enrollment information here: http://ccrtrial.com/current-studies/#!/study/54
Clinical Trial Details
Core Clinical Research is one of more than 90 sites in the U.S. participating in the study. The study is sponsored by New Haven-based Biohaven Pharmaceuticals. The study will enroll approximately 1,200 participants between the ages of 12 and 17 who will receive rimegepant or placebo for the investigational treatment of up to two migraine attacks of moderate to severe intensity. The effectiveness of rimegepant compared to placebo will be measured by freedom from pain at two hours post-dose.
About Migraine in Adolescents
Migraine is a debilitating neurological disease. In younger individuals, usually those under 15 years of age, migraine attacks may be bi-lateral (felt on both sides of the head) or unilateral (felt on only one side of the head), and may be non-throbbing. The child may look ill and pale, may feel dizzy, have blurred vision, and fever. Nausea and vomiting are frequent, particularly in young children (defined as seven years of age). Individuals with migraine tend to avoid light (photophobia), noise (phonophobia), strong odors, and movement.
April 10, 2022
Everett